The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Mazzacurati, Lucia, Collins, Robert J., Pandey, Garima, Lambert-Showers, Que T., Amin, Narmin E., Zhang, Ling, Stubbs, Matthew C., Epling-Burnette, Pearlie K., Koblish, Holly K., Reuther, Gary W.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880903/
https://ncbi.nlm.nih.gov/pubmed/31725895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000260
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires